Novartis' PI3K drug, already approved in breast cancer, nabs a speedy OK to treat ultra-rare condition

Half a year after Novartis showcased the potential of its PI3K inhibitor alpelisib among a group of young patients with an ultra-rare condition, the FDA has greenlighted the drug’s use based solely on real-world evidence.